Company intelligence
Alzinova AB
Swedish clinical stage biopharma company developing disease-modifying treatments against Alzheimer's disease.
About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.
Verified activity
Signals from Alzinova AB
2 published signals
Presence & Recognition
Alzinova AB welcomed neuroscience students from Karolinska Institutet and the DIS Study Abroad programme to GoCo Health Innovation City.
Reported by Alzinova AB
Presence & Recognition
Alzinova AB participated in a breakfast seminar on how Sweden can strengthen the link between research, innovation, and long-term value creation at GoCo Health Innovation City.
Reported by Alzinova AB